Kazuhiro Yoshida

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis

Tetsuya Ueda, Stefano Volinia, Hiroshi Okumura et al. · The Lancet Oncology · 2009 · 810 citations

Systems Biology, Engineering, Microrna Expression +12

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi et al. · Journal of Clinical Oncology · 2019 · 381 citations · Full text

A Multi‐institutional, Prospective, Phase II Feasibility Study of Laparoscopy‐Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901)

Noriyuki Inaki, Tsuyoshi Etoh, Tetsuji Ohyama et al. · World Journal of Surgery · 2015 · 299 citations

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8